All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

DONATE

Brought to you by

Scientific Education Support logo

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.

SubtypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-06-19T09:44:25.000Z

EHA 2019 | How can FDG-PET guide the treatment of patients with follicular lymphoma?

By Emily Smith, Stefano Luminari
Featured
Stefano Luminari
Jun 19, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Stefano Luminari from the University of Modena and Reggio Emilia, IT, discusses use of FDG-PET to guide the treatment of patients with follicular lymphoma (FL).

FDG-PET is used commonly in assessment of response in Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL). It's use in FL has been investigated both retrospectively and prospectively. The quality of response measured by FDG-PET, after standard immuno-chemotherapy, predicts individual relapse risk and progressive disease after induction and also in the maintenance setting. In this interview, Stefano Luminari discusses existing data, and the ongoing trials in this setting. The results of these trials will confirm whether response-adapted therapy based on the metabolic achievement of complete response is beneficial to the patients.

How can FDG-PET guide the treatment of patients with follicular lymphoma?

More about...
Aggressive B-cell lymphomasDiffuse large B-cell lymphomaEHA 2019FIL_FOLL12Follicular lymphomaGALLIUMHodgkin lymphomaHodgkin lymphoma, not otherwise specifiedIndolent B-cell lymphomasLenalidomideObinutuzumabPETReARituximab

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

New chemotherapy-free approaches for the treatment of lymphoid malignancies

At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances in chemotherapy-free options in the field of...

Jul 30, 2019
Add bookmark

New chemotherapy-free approaches for the treatment of lymphoid malignancies

At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances...

Jul 30, 2019
Add bookmark

ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Did you miss ASH 2018? The Lymphoma Hub has developed a downloadable resource, which provides information on the practice changing abstracts across...

Feb 21, 2019
Add bookmark

ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Did you miss ASH 2018? The Lymphoma Hub has developed a downloadable resource, which provides...

Feb 21, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox